You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Metsera
since
auto-detected in 22 stories
80 days ago
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
3 months ago
Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more ⊕
These are the stocks posting the largest moves midday.
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle ○
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
Pfizer wins $10bn bidding war for weight-loss start-up Metsera ○
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
Novo Nordisk again raises bid in battle for obesity start-up Metsera ⊖
found
a story from Financial Times ✅ › Financial Times
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera ⊕
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount ⊖
found
a story from CNBC ⚠️ › World News
Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer ○
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies ○
Improved pitches from both large pharma groups expected to be revealed later on Tuesday
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech ⊖⊖
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.